News Image

Let's take a look at the stocks that are in motion in today's session.

By Mill Chart

Last update: Apr 24, 2024

Which stocks are experiencing notable movement on Wednesday?

Top gainers

TickerChangeComment
CDTX2.0K%CIDARA THERAPEUTICS INC (NASDAQ:CDTX) experienced a significant 2.0K% increase, reaching $10.85 during Wednesday's session. In the last month the stock lost 31.34%.
CSSE122.0%Investors witnessed a remarkable 122.0% rise in CHICKEN SOUP FOR THE SOUL EN's (NASDAQ:CSSE) shares, which climbed to $0.34 during Wednesday's session. Shareholders saw the stock price going 56.71% lower is the past 6 months.
PBMWW57.83%PSYENCE BIOMEDICAL LTD's (NASDAQ:PBMWW) shares rose 57.83% to $0.09 during Wednesday's session. The stock is trading 44.39% lower than a month ago.
LICN53.41%With a 53.41% surge, LICHEN CHINA LTD- A's (NASDAQ:LICN) stock price reached $0.86 during Wednesday's session, signaling positive momentum. In the last month the stock lost 47.66%.
WIMI40.41%WIMI HOLOGRAM CLOUD INC-ADR (NASDAQ:WIMI) rose 40.41% to $1.02 during Wednesday's after hours session. In the last month the share price dropped with 23.19%.
MULN38.46%MULLEN AUTOMOTIVE INC's (NASDAQ:MULN) stock price is advancing with 38.46% to a price of $3.78. In the last month the stock lost 40.0%.
AIRE33.28%Exciting news for REALPHA TECH CORP (NASDAQ:AIRE) as its stock price surged 33.28% to $0.81 during Wednesday's session. Earlier today the company had a press release: reAlpha Tech Corp. Launches Claire, Real Estate’s First AI-powered, Zero-Commission Smart Buyer’s Agent.
PRE32.17%PRENETICS GLOBAL LTD-CL A's (NASDAQ:PRE) stock price displayed strong growth, advancing 32.17% and reaching $6.04 during Wednesday's session. In the last year the stock lost 63.15%.
RBBN30.28%RIBBON COMMUNICATIONS INC's (NASDAQ:RBBN) stock price is advancing with 30.28% to a price of $3.35. The company's earnings where released Yesterday. Shareholders saw the stock price going 23.56% higher is the past 6 months.
RCAT29.17%RED CAT HOLDINGS INC (NASDAQ:RCAT) witnessed a notable 29.17% uptick in its shares, reaching $1.55 during Wednesday's session. Shareholders saw the stock price going 54.7% higher in the past month.

For the full top gainers list go to our top gainers page.

Back

CIDARA THERAPEUTICS INC

NASDAQ:CDTX (5/17/2024, 7:00:03 PM)

11.21

-0.79 (-6.58%)

CDTX News

News Image2 days ago - TheNewswire.comCDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

WHY: NEW YORK, NY - (NewMediaWire) - May 16, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cidara Therapeutics, Inc. (NASDAQ: CDTX) resulting from allegations that Cidara Therapeutics may have issued materially misleading business information to the investing public.

News Image2 days ago - NewMediaWireCDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image3 days ago - BusinessInsiderCDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cidara Therapeutics (NASDAQ:CDTX) just reported results for the first quarter o...

News Image3 days ago - InvestorPlaceCDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024

CDTX stock results show that Cidara Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

News Image3 days ago - Cidara Therapeutics, Inc. Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary...

News Image3 days ago - Cidara Therapeutics, Inc. Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform...

News Image4 days ago - The Rosen Law Firm PACDTX INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
News Image5 days ago - TheNewswire.comCDTX LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

WHY: NEW YORK, NY - (NewMediaWire) - May 13, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara Therapeutics, Inc. (NASDAQ: CDTX) resulting from allegations that Cidara Therapeutics may have issued materially misleading business information to the investing public.

News Image5 days ago - NewMediaWireCDTX LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image8 days ago - THE ROSEN LAW FIRM, P. A.CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...

News Image23 days ago - Cidara Therapeutics, Inc. Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024

SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary...

News Image23 days ago - Bragar Eagel & SquireCIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm
CDTX Links
Follow us for more